Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Long Term Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Central Neuropathy of Any Genesis

NCT06072001 is registered in ClinicalTrials.gov with Apurano Pharmaceuticals GmbH as lead sponsor.

NCT NCT06072001
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06072001 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Long Term Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Central Neuropathy of Any Genesis
Lead sponsor
Apurano Pharmaceuticals GmbH
Phase
Phase 3
Overall status
Unknown status
Start date
November 2, 2023
Completion date
December 31, 2024
Enrollment
558 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

central neuropathic pain, chronic pain, chronic pain syndrome, multiple sclerosis, neuropathic pain, pain, pain syndrome, pain, chronic, paraplegia, phantom limb syndrome with pain, phantom pain, stroke, traumatic brain injury